SCHEDULE 13D/A: EcoR1 Capital Boosts Zymeworks Stake to 22.4%, Signals Activist Intent

EcoR1 Capital, LLC and its affiliates have increased their beneficial ownership in Zymeworks Inc. to 22.4% of outstanding common stock, reiterating their belief in the company's undervaluation and potential for strategic influence.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. collectively beneficially own 15,411,078 shares of Zymeworks Inc. Common Stock, representing 22.4% of the class.
• This percentage is calculated based on 68,877,526 shares of Common Stock outstanding as of October 30, 2024, as reported in Zymeworks' Form 10-Q for the quarter ended September 30, 2024.
• The reporting persons acquired the shares for investment purposes, believing Zymeworks' Common Stock was undervalued and presented an attractive investment opportunity.
• Funds used for purchasing Common Stock and Pre-Funded Warrants totaled $117,035,093.68 for EcoR1 Capital Fund Qualified, L.P. and $8,362,904.44 for EcoR1 Capital Fund, L.P. for Common Stock.
• An additional $47,364,999.62 for EcoR1 Capital Fund Qualified, L.P. and $2,634,993.17 for EcoR1 Capital Fund, L.P. were used for Pre-Funded Warrants.
• The reporting persons recently purchased Zymeworks Common Stock on multiple dates in December 2024 and January 2025, with dollar-weighted average prices ranging from $13.126 to $14.7796 per share.
• These purchases include 11,958 shares on 12/24/2024, 16,692 shares on 12/26/2024, 101,659 shares on 12/27/2024, 58,988 shares on 12/30/2024, 146,501 shares on 12/31/2024, 157,880 shares on 1/2/2025, 21,021 shares on 1/8/2025, and 204,098 shares on 1/10/2025.
• The reporting persons hold 5,086,521 Pre-Funded Warrants, which are currently not exercisable due to a 19.99% beneficial ownership limitation.
• EcoR1's employee, Scott Platshon, serves on Zymeworks' board of directors, a right granted through a previous securities purchase agreement.

Sentiment

Score: 8

Explanation: The sentiment is positive due to a major investment firm increasing its stake, explicitly stating the company is undervalued, and having a board representative, indicating a strong belief in future value creation and potential for strategic improvements.

Positives

• A significant increase in beneficial ownership by a major investment firm (EcoR1 Capital) signals strong confidence in Zymeworks' long-term value.
• The reporting persons explicitly state their belief that Zymeworks' Common Stock was undervalued, suggesting potential upside.
• EcoR1 Capital has a representative on Zymeworks' board of directors, providing direct influence and oversight.
• The reporting persons' willingness to engage with management and the board could lead to strategic initiatives that enhance shareholder value.

Risks

• The Issuer is subject to liquidated damages if the registration statement for the resale of Warrant Shares is not filed or declared effective by specified deadlines, or if sales cannot be made under it.
• Liquidated damages are set at 1% of the aggregate purchase price for each 30-day period of non-compliance, capped at 6% of the aggregate purchase price.
• The Pre-Funded Warrants are subject to a 19.99% beneficial ownership limitation, restricting immediate full exercise and potentially limiting the reporting persons' ability to increase their voting power beyond this threshold without prior notice.

Future Outlook

The reporting persons intend to routinely monitor Zymeworks Inc. regarding various factors, including trading prices, operations, financial position, and strategic matters. They may purchase additional Common Stock, sell existing holdings, or engage in hedging transactions. While they have no present plan for specific corporate actions, they may recommend actions to the Issuer's management, board of directors, and stockholders, potentially involving mergers, consolidations, asset sales, changes in control, or other capital structure adjustments.

Management Comments

• "The reporting persons acquired the Stock for investment purposes based on their belief that the Issuer's Common Stock, when purchased, was undervalued and represented an attractive investment opportunity."
• "The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations..."
• "The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the reporting persons may recommend action to the Issuer's management, board of directors and stockholders."

Industry Context

This filing indicates a significant activist stake by EcoR1 Capital, a specialized healthcare and biotechnology investment firm, in Zymeworks Inc., a clinical-stage biopharmaceutical company. Such large stakes and board representation are common in the biotech industry where investors often seek to influence strategic direction, R&D priorities, or M&A activities to unlock perceived value in companies with promising but potentially undervalued pipelines.

Management Changes

Corporate Governance

Related Party Transactions

• Securities Purchase Agreement, dated December 23, 2023, between the Issuer and the reporting persons for the private placement of Pre-Funded Warrants.
• Registration Rights Agreement, dated December 23, 2023, between the Issuer and the reporting persons, requiring the Issuer to register the resale of the Warrant Shares.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic changes or improved governance driven by a significant activist investor.
• Management: Increased scrutiny and potential pressure to implement changes recommended by EcoR1 Capital.
• Employees: Potential for strategic shifts could impact organizational structure or priorities.
• Creditors: Changes in capital structure or strategic direction could indirectly affect credit risk perception.

Next Steps

• Reporting persons will continue to monitor Zymeworks Inc.'s performance, operations, and market conditions.
• Reporting persons may purchase additional Common Stock or other securities of Zymeworks Inc. in the open market or through private transactions.
• Reporting persons may sell all or part of their holdings in Zymeworks Inc. at any time.
• Reporting persons may enter into or unwind hedging or other derivative transactions related to Zymeworks Common Stock.
• Reporting persons may communicate with other stockholders, industry participants, and interested parties about Zymeworks Inc.
• Reporting persons may recommend actions to Zymeworks' management, board of directors, and stockholders, potentially including strategic changes like mergers, acquisitions, or changes in capitalization.

Key Dates

Keywords

Zymeworks Inc., EcoR1 Capital, Schedule 13D, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Investment Strategy, Biotechnology, Activist Investor, Corporate Governance